Medical : Oncology

The discovery of p53 in 1979 marks the beginning of a most fascinating era of modern cancer research and molecular biology, an era that is still in full swing and does not show any signs of ending in the foreseeable future. p53 has emerged as a key tumor suppressor and important target for novel cancer therapy. For around 10 years, p53 was considered an oncogene with somewhat unusual features. However, a major paradigm shift occurred around 1988-89 when exciting new findings demonstrated that normal (wild type) p53 could inhibit transformation of cells in culture and that the p53 gene was mutated in a large fraction of human tumors. In fact, p53 appeared to be the most frequently mutated gene in cancer cells. Subsequent work during the 1990’s showed that p53 was a transcription factor that regulates many other genes, and that p53 can trigger apoptosis, the suicide program of the cell. more...

Price: $195.00

This brand new edition pulls together the most up-to-date information on this complex, multidisciplinary area in a practical, user-friendly manner. It deals with the important social and psychological aspects for palliative care of people with incurable diseases including quality of life, communication and bereavement issues. more...

Price: $44.95

Adenoviral Vectors for Gene Therapy provides detailed and comprehensive coverage of these important therapeutic agents. The topics covered in this book range from the basic biology of adenoviruses, through the construction and purification of adenoviral vectors, cutting-edge vectorology and the use of adenoviral vectors in preclinical animal models, to regulatory issues which must be considered prior to the initiation of human clinical gene therapy trials. The broad scope of this unique volume provides the reader with a complete understanding of the development and use of adenoviral vectors. more...

Price: $225.00

Over the last 5 years significant advances have been made in our understanding of the biology of breast cancer. As a result of linking observations made in the laboratory to new treatment strategies, the outcome of breast cancer patients with both early and late stage disease has continued to improve. This volume will highlight many of the important advances that have improved our understanding of the biology and therapeutics of breast cancer. The initial discussion will focus on the evolving understanding of the genetics of breast cancer. (Olapade or Pasche) In addition to the well known genetic mutations BRCA1 and BRCA2, other mutations that have recently been identified will be discussed. In addition, strategies for surveillance of high-risk populations and prevention strategies under evaluation are highlighted. The underlying molecular pathways that control malignant cell growth are being better characterized thru laboratory investigation and as a result of this work numerous novel therapeutics that target these pathways in already in the clinic to define whether there is clinical benefit in breast cancer patients. Dr Pegram will discuss the rationale for development of some of the agents farthest along in clinical development. Though novel therapeutic agents or "targeted therapy" hold significant promise, standard treatment modalities including chemotherapy, endocrine therapy, surgery and radiation therapy will remain important for management of breast cancer patients. The decision to offer patients with early stage breast cancer systemic adjuvant therapy has been made based largely on clinical parameters including tumor size and nodal status. Clinicians have longrecognized that this method of evaluating risk of recurrence for an individual patient is imprecise. Much research over the last several years has focused on developing molecular profiles of individual tumors that correlate with long-term outcome. Dr. Paik will discuss the development of this more...

Price: $139.00

Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here once again, outstanding and original reviews are presented. more...

Price: $150.00